학술논문
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
Document Type
Article
Author
Sigaud, R.; Rösch, L.; Gatzweiler, C.; Benzel, J.; von Soosten, L.; Peterziel, H.; Selt, F.; Najafi, S.; Ayhan, S.; Gerloff, X.F.; Hofmann, N.; Büdenbender, I.; Schmitt, L.; van Tilburg, C.M.; Jones, D.T.W.; Pfister, S.M.; Pajtler, K.W.; Zuckermann, M.; Oehme, I.; Witt, O.; Milde, T.; Foerster, K.I.; Burhenne, J.; Haefeli, W.E.; Sauter, M.; Korshunov, A.; Sahm, F.; Knoerzer, D.; Kreider, B.L.
Source
In: Neuro-oncology . (Neuro-oncology, 14 March 2023, 25(3):566-579)
Subject
Language
English
ISSN
15235866